Welcome to a Scientific seminar by InFLAMES Visiting Professor Andy Chan!

Speaker: Andy Chan
Title: Evolving drug modalities from antibodies to in vivo cell programming to treat autoimmune diseases
Time: 10 June 2026, 11-12
Location: Arje Scheinin, Dentalia
Host: Professor of Practice Timo Veromaa, InFLAMES Flagship

Coffee and sandwiches will be served before the seminar.

Biography

Dr. Andrew Chan is a former Senior Vice President of Research-Biology at Genentech, Inc where he oversaw biological research across all therapeutic areas including oncology, immunology, neuroscience, infectious diseases and regenerative medicine. He is a leader in biotherapeutics discovery and development and integrates lessons learned about disease pathogenesis and mechanisms of therapy.

Chan’s research focuses on how our immune systems protect us against foreign pathogens and yet cause autoimmune and inflammatory diseases. Chan is also co-inventor of ocrelizumab (Ocrevus™), the first B-cell directed therapy approved by the FDA for treatment of both relapsing and progressive forms of multiple sclerosis.